Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
ATAI Life Sciences N.V. - Common Shares
(NQ:
ATAI
)
2.710
+0.520 (+23.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about ATAI Life Sciences N.V. - Common Shares
< Previous
1
2
3
4
Next >
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
July 01, 2025
From
FN Media Group LLC
Via
GlobeNewswire
atai Life Sciences Announces $50 Million Private Placement Financing
July 01, 2025
Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1
From
atai Life Sciences
Via
GlobeNewswire
DOD to Invest $9.8m into Psychedelic Studies Targeting Active-Duty Soldiers
March 19, 2025
Via
Investor Brand Network
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
July 01, 2025
EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders
June 15, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
July 01, 2025
From
atai Life Sciences
Via
GlobeNewswire
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders
June 03, 2025
From
Halper Sadeh LLC
Via
Business Wire
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
June 02, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences to Participate in Upcoming Investor Conferences
May 29, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
May 20, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
May 14, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
May 13, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
March 17, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
March 11, 2025
From
atai Life Sciences
Via
GlobeNewswire
Study Finds That Bad Psychedelic Trips Double Some Individuals’ Fatality Risk
March 05, 2025
Via
Investor Brand Network
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
March 05, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
February 24, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
February 20, 2025
From
atai Life Sciences
Via
GlobeNewswire
Veterans Turn to One Another for Help Using Psychedelics to Combat Mental Health Challenges
February 19, 2025
Via
Investor Brand Network
atai Life Sciences Announces Pricing of Public Offering of Common Shares
February 12, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Proposed Public Offering of Common Shares
February 12, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
January 28, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
January 10, 2025
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 13, 2024
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
October 15, 2024
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 13, 2024
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
August 13, 2024
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
June 26, 2024
From
atai Life Sciences
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.